Akari Therapeutics Plc Quarterly Cash and Cash Equivalents, at Carrying Value in USD from Q4 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Summary
Akari Therapeutics Plc quarterly Cash and Cash Equivalents, at Carrying Value history and growth rate from Q4 2010 to Q2 2024.
  • Akari Therapeutics Plc Cash and Cash Equivalents, at Carrying Value for the quarter ending June 30, 2024 was $236K, a 9.99% increase year-over-year.
Cash and Cash Equivalents, at Carrying Value, Quarterly (USD)
Cash and Cash Equivalents, at Carrying Value, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $236K +$21.4K +9.99% Jun 30, 2024 8-K 2024-09-06
Q1 2024 $1.31M Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $382K -$273K -41.7% Dec 31, 2023 8-K 2024-09-06
Q2 2023 $214K -$7.94M -97.4% Jun 30, 2023 8-K 2024-09-06
Q4 2022 $655K -$8.71M -93% Dec 31, 2022 8-K 2024-09-06
Q2 2022 $8.15M +$4.36M +115% Jun 30, 2022 6-K 2022-09-27
Q4 2021 $9.36M -$4.69M -33.4% Dec 31, 2021 20-F 2023-05-01
Q2 2021 $3.79M -$8.95M -70.3% Jun 30, 2021 6-K 2021-09-22
Q4 2020 $14.1M +$8.32M +145% Dec 31, 2020 20-F 2022-05-16
Q3 2020 $12.3M +$6.05M +96.5% Sep 30, 2020 20-F 2021-04-21
Q2 2020 $12.7M +$10M +366% Jun 30, 2020 20-F 2021-04-21
Q1 2020 $7.82M +$1.68M +27.3% Mar 31, 2020 20-F 2021-04-21
Q4 2019 $5.73M +$286K +5.24% Dec 31, 2019 20-F 2021-04-21
Q3 2019 $6.27M Sep 30, 2019 20-F 2021-04-21
Q2 2019 $2.74M -$12.3M -81.8% Jun 30, 2019 20-F 2021-04-21
Q1 2019 $6.15M Mar 31, 2019 20-F 2021-04-21
Q4 2018 $5.45M -$22.7M -80.6% Dec 31, 2018 20-F 2020-03-31
Q2 2018 $15.1M -$15M -50% Jun 30, 2018 6-K 2018-09-27
Q4 2017 $28.1M -$5.99M -17.6% Dec 31, 2017 20-F 2020-03-31
Q2 2017 $30.1M +$20.5M +212% Jun 30, 2017 6-K 2018-09-27
Q4 2016 $34.1M -$34.8M -50.5% Dec 31, 2016 6-K 2018-09-27
Q2 2016 $9.66M +$9.46M +4697% Jun 30, 2016 6-K 2017-08-10
Q1 2016 $61.4M +$60.1M +4523% Mar 31, 2016 10-Q 2016-05-12
Q4 2015 $68.9M +$65.6M +1971% Dec 31, 2015 20-F 2018-07-18
Q3 2015 $78.8M +$78.7M +149618% Sep 30, 2015 10-Q 2015-11-23
Q2 2015 $201K -$11.2M -98.2% Jun 30, 2015 6-K/A 2017-04-14
Q1 2015 $1.33M -$12.5M -90.4% Mar 31, 2015 10-Q 2016-05-12
Q4 2014 $3.33M +$2.77M +501% Dec 31, 2014 20-F 2018-07-18
Q3 2014 $52.6K Sep 30, 2014 10-Q 2015-11-23
Q2 2014 $11.4M Jun 30, 2014 10-Q 2015-08-12
Q1 2014 $13.8M Mar 31, 2014 10-Q 2015-05-12
Q4 2013 $554K -$550K -49.9% Dec 31, 2013 20-F 2017-03-31
Q4 2012 $1.1M -$4.9M -81.6% Dec 31, 2012 10-K 2015-02-11
Q4 2011 $6M +$5.99M Dec 31, 2011 10-K 2015-02-11
Q4 2010 $9K* Dec 31, 2010 20-F 2014-03-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.